RDiscovery

Founder and Managing Partner with over 31 years of business experience, including 21 years in life science startup financing and company creation. Previously managed the biopharma investment team at Mitsui divisions.

Over 20 years in search, evaluation, business development, and venture investment. Previously Vice President of Corporate Development at Ora and spent 13+ years at Daiichi-Sankyo identifying opportunities from discovery through late clinical stage.

Over 20 years of experience in drug discovery, licensing, and technology evaluation. Engaged in technology sourcing, company creation, and investment negotiations. Previously worked at Nippon Boehringer Ingelheim in Japanese innovative seed evaluation.

Over 20 years of business development and venture investment experience. Engaged in technology sourcing, company creation, and investment negotiations. Previously held multiple roles at Mitsui including board member and acting management positions.

Serial entrepreneur and venture partner with over 25 years in corporate development across licensing, M&A, and strategic alliances. Cofounder and Chief Business Officer of Vincerx, which went public on NASDAQ in 2020. Led business development at Supergen closing strategic alliances with GSK and M&A with Astex.

16 years in research and development of drug delivery system technology for nucleic acid drugs at a bio-venture company, with experience from basic research through clinical trials including pharmacodynamics and biomarker measurement.

Chief Medical Officer with over 30 years of clinical practice and medical research experience across academia and industry. Spent 18 years at Pfizer, Merck, and Bristol Myers Squibb in R&D, marketing, and business development. Previously led clinical development at Luzsana Biotechnology.

Approximately 10 years in applied biotech research at a major electronics manufacturer, followed by over 8 years in basic research at drug discovery ventures. Served as group leader of new compound development before joining RDiscovery.

Over 18 years in drug discovery, patent practice, and technology transfer. Previously worked at Tohoku Techno Arch conducting technology evaluation, patent application, and license negotiation in the biotech area.

Seven years at drug discovery venture NapaJen Pharma as lab manager overseeing in vitro pharmacological studies. Engaged in drug discovery research experiments since 2021.

Studied transplantation immunology at Harvard and conducted clinical and research work on cardiac regeneration. Founded IMEL Biotherapeutics for mitochondrial disease therapies using proprietary mitochondrial genome replacement technology. Engaged in organelle therapy research.

Pharmaceutical scientist with expertise in molecular biology and immunology. Conducted basic research at UCLA, University of Toronto, and RIKEN, followed by open innovation roles at Bayer, Abbvie, and Boehringer Ingelheim. Currently accelerates academia-industry partnerships at Kyoto University.

Over 28 years in business development, healthcare consulting, and venture investment. Spent 12 years at Mitsui Ventures holding board positions in 10 portfolio companies. Previously spent 6 years at Cambridge Pharma Consultancy advising on pharmaceutical pricing and market access.